Health-related quality of life (HRQoL) in AVAglio, a randomized, placebo (P)-controlled phase III study of bevacizumab (B), temozolomide (T) and radiotherapy (RI) in patients (pts) with newly diagnosed glioblastoma (GBM)

被引：0
|
作者：
Bottomley, A. [1 ]
Henrikkson, R. [2 ,3 ]
Taphoorn, M. J. B. [4 ,5 ]
Cloughesy, T. [6 ]
Wick, W. [7 ]
Mason, W. [8 ]
Saran, F. [9 ]
Nishikawa, R. [10 ]
Ravelo, A. [11 ]
Chinot, O. L. [12 ]
机构：
[1] EORTC, Qual Life Dept, Brussels, Belgium
[2] Reg Canc Ctr Stockholm, Stockholm, Sweden
[3] Umea Univ, Dept Radiotherapy & Oncol, Stockholm, Sweden
[4] Med Ctr Haaglanden Hague, Amsterdam, Netherlands
[5] Vrije Univ Amsterdam Med Ctr, Dept Neurol, Amsterdam, Netherlands
[6] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA
[7] Univ Med Ctr, Dept Neurooncol, Heidelberg, Germany
[8] Univ Toronto, Princess Margaret Hosp, Fac Med, Toronto, ON, Canada
[9] Royal Marsden NHS Fdn Trust, Neurooncol Unit, Sutton, Surrey, England
[10] Saitama Med Univ, Dept Neurooncol Neurosurg, Int Med Ctr, Saitama, Japan
[11] Genentech Inc, Clin Pharmacol, San Francisco, CA 94080 USA
[12] Aix Marseille Univ, CHU Timone, AP HM, Serv Neurooncol, Marseille, France
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3316
引用
收藏
页码：S780 / S780
页数：1
相关论文
共 50 条
  • [41] Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial
    Verelst, Silvia G. R.
    Termorshuizen, F.
    Uyl-de Groot, C. A.
    Schaafsma, M. R.
    Ammerlaan, A. H. M.
    Wittebol, S.
    Sinnige, H. A. M.
    Zweegman, S.
    Kooy, M. van Marwijk
    van der Griend, R.
    Lokhorst, H. M.
    Sonneveld, P.
    Wijermans, P. W.
    ANNALS OF HEMATOLOGY, 2011, 90 (12) : 1427 - 1439
  • [42] Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study
    Mesa, Ruben A.
    Schaap, Nicolaas
    Vannucchi, Alessandro M.
    Kiladjian, Jean-Jacques
    Passamonti, Francesco
    Zweegman, Sonja
    Talpaz, Moshe
    Verstovsek, Srdan
    Rose, Shelonitda
    Tang, Derek
    Hu, Angela
    Brownstein, Carrie
    Guo, Shien
    Ye, Xiaomei
    Harrison, Claire N.
    BLOOD, 2019, 134
  • [43] Effect of Thalidomide with Melphalan and Prednisone on Health-Related Quality of Life (HRQoL) in Elderly Patients with Newly Diagnosed Multiple Myeloma: A Prospective Analysis In a Randomized Trial
    Verelst, S.
    Termorshuizen, F.
    Uyl-de Groot, C.
    Schaafsma, M. R.
    Ammerlaan, R.
    Wittebol, S.
    Sinnige, H.
    Zweegman, S.
    Kooy, M. van Marwijk
    van der Griend, R.
    Lokhorst, H.
    Sonneveld, P.
    Wijermans, P.
    BLOOD, 2010, 116 (21) : 1225 - 1226
  • [44] Health-related quality of life in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only: Secondary outcome of the randomized phase III EORTC 26101 study
    Dirven, Linda
    Machingura, Abigirl
    van den Bent, Martin J.
    Coens, Corneel
    Bottomley, Andrew
    Brandes, Alba A.
    Domont, Julien
    Idbaih, Ahmed
    Koekkoek, Johan A. F.
    Reijneveld, Jaap C.
    Platten, Michael
    Wick, Wolfgang
    Taphoorn, Martin J. B.
    NEURO-ONCOLOGY PRACTICE, 2024,
  • [45] Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AV Aglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM)
    Wick, Wolfgang
    Cloughesy, Timothy Francis
    Nishikawa, Ryo
    Mason, Warren
    Saran, Frank
    Henriksson, Roger
    Hilton, Magalie
    Kerloeguen, Yannick
    Chinot, Oliver L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] Impact of bevacizumab added to temozolomide-chemoradiation on time to health-related quality of life deterioration in unresectable glioblastoma: results of a phase II randomized clinical trial
    Anota, Amelie
    Dabakuyo, Tienhan Sandrine
    Pozet, Astrid
    Paquette, Brice
    Feuvret, Loic
    Taillandier, Luc
    Frappaz, Didier
    Taillia, Herve
    Schott, Roland
    Fabbro, Michel
    Tennevet, Isabelle
    Ghiringhelli, Francois
    Dalban, Cecile
    Skrzypski, Jerome
    Chinot, Olivier
    Chauffert, Bruno
    Bonnetain, Franck
    QUALITY OF LIFE RESEARCH, 2015, 24 : 15 - 16
  • [47] Impact of bevacizumab added to temozolomide-chemoradiation on time to health-related quality of life deterioration in unresectable glioblastoma: Results of a phase II randomized clinical trial
    Bonnetain, Franck
    Dabakuyo, Tienhan Sandrine
    Pozet, Astrid
    Feuvret, Loic
    Taillandier, Luc
    Frappaz, Didier
    Taillia, Herve
    Schott, Roland
    Honnorat, Jerome
    Fabbro, Michel
    Tennevet, Isabelle
    Ghiringhelli, Francois
    Campello, Chantal
    Castera, Daniel
    Frenay, Marc
    Dalban, Cecile
    Skrzypski, Jeremy
    Chinot, Olivier L.
    Chauffert, Bruno
    Anota, Amelie
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] Health-related quality of life (HRQoL) of patients with advanced gastrointestinal stromal tumors (GIST) treated with regorafenib (REG) vs placebo (P) in the phase III GRID trial
    Bauer, S.
    Chang, J.
    Casali, P. G.
    Reichardt, P.
    Kang, Y-K
    Blay, J-Y
    Wu, Y.
    Odom, D.
    Kuss, I.
    Demetri, G. D.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 58 - 58
  • [49] Health-related quality of life (HRQoL) of patients with advanced gastrointestinal stromal tumors (GIST) treated with regorafenib (REG) vs placebo (P) in the phase III GRID trial
    Chang, J.
    Casali, P. G.
    Reichardt, P.
    Kang, Y. K.
    Blay, J. Y.
    Wu, Y.
    Odom, D.
    Kuss, I.
    Demetri, G. D.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S886 - S886
  • [50] HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TIE NDMM) AND RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN PHASE III RANDOMIZED CONTROLLED TRIALS (RCTS): A TARGETED LITERATURE REVIEW
    Charu, R.
    Manupati, R.
    Singh, J. A.
    Rai, M. K.
    Gautam, R.
    Kalsey, M. S.
    Prasanna, R.
    VALUE IN HEALTH, 2022, 25 (07) : S546 - S546
12345